Yvonne Marie Jordan, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 32413 Ny Rte. 12, Depauville, NY 13632 Phone: 315-686-2989 |
News Archive
Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in Europe, including most countries in the European Union, Turkey, Switzerland, Norway, the Balkan countries and Iceland. Terms of the agreement were not disclosed. Cerimon initially acquired the U.S. rights to develop and commercialize the patch formulation of diclofenac in 2005.
The VTT spin-off, VitalSignum, is making a small mobile device - which detects arrhythmia by measuring the patient's ECG - available to consumers. The first production batch is being completed and will be retailed to consumers in early October.
As the drive to commercialize graphene continues, it is important that all safety aspects are thoroughly researched and understood.
Severe COVID-19 causes sepsis-like manifestations, intense lung injury, and multi-organ failure, all associated with the overproduction of pro-inflammatory cytokines. This "cytokine storm" directly correlates with poor prognosis in this subgroup of patients.
› Verified 9 days ago